The application of immune checkpoint inhibitors (ICI), including antibodies against programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte protein 4 (CTLA-4) significantly increased survival and response rates for advanced melanoma patients (6). This evidence concerns the gene PDCD1 and melanoma.